Literature DB >> 1362438

The inflammatory myelinopathy of adreno-leukodystrophy: cells, effector molecules, and pathogenetic implications.

J M Powers1, Y Liu, A B Moser, H W Moser.   

Abstract

Prominent inflammation in the demyelinative lesion of adreno-leukodystrophy (ALD) has suggested an immune-mediated pathogenetic component. Commercially available antibodies to T cells, B cells, macrophages, class I and II molecules, complement, IgG, IgM, IgA, interleukin-1 (IL-1), intercellular adhesion molecule-1 (ICAM-1) and tumor necrosis factor-alpha (TNF) were applied to paraffin sections of formaldehyde-fixed postmortem samples. Twenty-five primary demyelinative lesions from five juvenile ALD, three adult ALD, and three adrenomyeloneuropathic patients were evaluated with appropriate positive and negative controls. Macrophages and astrocytes were the predominant cells detected at the active edge; T lymphocytes, including T4 and CD45R subsets, were nearly as numerous but usually located around vessels within the lesion. B cells and plasma cells, usually containing IgG, were uncommon. The expression of class II molecules, restricted to one adult, was problematic; class I expression was increased in microvascular and other cells. Degraded myelin was labeled with antibodies to C3d and IL-1; IL-1 and ICAM-1 immunoreactivity was seen on microvessels and astrocytes. Tumor necrosis factor-alpha immunoreactivity was detected in macrophages, but more prominently in astrocytes. These data support a natural immune response in the demyelinative lesion of ALD, consisting predominantly of reactive astrocytes, macrophages, T cells and cytokines. A two-stage pathogenetic theory is discussed. The postulated roles of TNF and reactive astrocytes, in concert with a fundamental myelinolytic biochemical defect, suggest a different pathogenetic mechanism and raise novel therapeutic possibilities.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1362438     DOI: 10.1097/00005072-199211000-00007

Source DB:  PubMed          Journal:  J Neuropathol Exp Neurol        ISSN: 0022-3069            Impact factor:   3.685


  62 in total

1.  Progression of abnormalities in adrenomyeloneuropathy and neurologically asymptomatic X-linked adrenoleukodystrophy despite treatment with "Lorenzo's oil".

Authors:  B M van Geel; J Assies; E B Haverkort; J H Koelman; B Verbeeten; R J Wanders; P G Barth
Journal:  J Neurol Neurosurg Psychiatry       Date:  1999-09       Impact factor: 10.154

2.  Isolation and biochemical characterization of peroxisomes from cultured rat glial cells.

Authors:  I Singh; O Carillo; A Namboodiri
Journal:  Neurochem Res       Date:  2000-02       Impact factor: 3.996

3.  X-linked adrenoleukodystrophy: first report of the Italian Study Group.

Authors:  A Di Biase; S Salvati; C Avellino; M Cappa; E Bertini; I Moroni; M Rimoldi; G Uziel
Journal:  Ital J Neurol Sci       Date:  1998-10

Review 4.  X linked adrenoleukodystrophy: clinical presentation, diagnosis, and therapy.

Authors:  B M van Geel; J Assies; R J Wanders; P G Barth
Journal:  J Neurol Neurosurg Psychiatry       Date:  1997-07       Impact factor: 10.154

Review 5.  On the front of X-linked adrenoleukodystrophy.

Authors:  P Aubourg
Journal:  Neurochem Res       Date:  1999-04       Impact factor: 3.996

Review 6.  Evaluation of therapy of X-linked adrenoleukodystrophy.

Authors:  Hugo W Moser; Ali Fatemi; Kathleen Zackowski; Seth Smith; Xavier Golay; Larry Muenz; Gerald Raymond
Journal:  Neurochem Res       Date:  2004-05       Impact factor: 3.996

7.  Intensity of MRI Gadolinium Enhancement in Cerebral Adrenoleukodystrophy: A Biomarker for Inflammation and Predictor of Outcome following Transplantation in Higher Risk Patients.

Authors:  W P Miller; L F Mantovani; J Muzic; J B Rykken; R S Gawande; T C Lund; R M Shanley; G V Raymond; P J Orchard; D R Nascene
Journal:  AJNR Am J Neuroradiol       Date:  2015-10-01       Impact factor: 3.825

8.  Conserved fatty acid composition of proteolipid protein during brain development and in myelin subfractions.

Authors:  A M Messier; O A Bizzozero
Journal:  Neurochem Res       Date:  2000-04       Impact factor: 3.996

Review 9.  Very long-chain fatty acids in diagnosis, pathogenesis, and therapy of peroxisomal disorders.

Authors:  H W Moser; A B Moser
Journal:  Lipids       Date:  1996-03       Impact factor: 1.880

10.  Failure of beta interferon therapy in X-linked adrenoleukodystrophy.

Authors:  G C Korenke; H J Christen; D H Hunneman; F Hanefeld
Journal:  Eur J Pediatr       Date:  1996-09       Impact factor: 3.183

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.